US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tvardi Therapeutics Inc

17.47

+0.43092.53%

Post-market: 17.470.00000.00%17:00 EDT

Volume:10.31K

Turnover:176.81K

Market Cap:163.44M

PE:-1.12

High:18.75

Open:16.10

Low:15.80

Close:17.04

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Tvardi Therapeutics Inc

Exchange:

NASDAQ

Establishment Date:

2017

Employees:

- -

Office Location:

3 Sugar Creek Center Boulevard,Suite 525,Sugar Land,Texas,United States

Website:

http://tvarditherapeutics.com

Zip Code:

77478

Phone:

Fax:

- -

Introduction:

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Directors

Name

Position

Derek Chalmers

Director,President and Chief Executive Officer

Dean Slagel

Director

Harrison M. Bains, Jr.

Director

Jeffrey L. Ives

Director

Martin Vogelbaum

Director

Shareholders

Name

Position

Derek Chalmers

Director,President and Chief Executive Officer

Josef Schoell

Treasurer, Chief Financial Officer

Frederique Menzaghi

Vice President - Research and Development

Joseph Stauffer

Chief Medical Officer

Michael E. Lewis

Chief Scientific Advisor

Scott M. Terrillion

General Counsel, Secretary

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TVRD/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":17.47,"timestamp":1745265600000,"preClose":17.0391,"halted":0,"volume":10312,"hourTrading":{"tag":"盘后","latestPrice":17.47,"preClose":17.47,"latestTime":"17:00 EDT","volume":23,"amount":394.22,"timestamp":1745269215008},"delay":0,"floatShares":3316400,"shares":9355542,"eps":-15.531682,"marketStatus":"Closed","change":0.4309,"latestTime":"04-21 16:00:00 EDT","open":16.1,"high":18.75,"low":15.8,"amount":176807.757712,"amplitude":0.173131,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-15.531682,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745308800000},"marketStatusCode":5,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":17.0391,"preHourTrading":{"tag":"盘前","latestPrice":14.7,"preClose":17,"latestTime":"08:56 EDT","volume":46,"amount":588.9500059999999,"timestamp":1745240205791},"postHourTrading":{"tag":"盘后","latestPrice":17.47,"preClose":17.47,"latestTime":"17:00 EDT","volume":23,"amount":394.22,"timestamp":1745269215008},"volumeRatio":0.256204},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":3316400,"roa":"--","roe":"--","lyrEps":-15.531682,"volumeRatio":0.256204,"shares":9355542,"dividePrice":0,"high":18.75,"amplitude":0.173131,"preClose":17.0391,"low":15.8,"week52Low":8.1252,"pbRate":"--","week52High":31.32,"institutionHeld":0,"latestPrice":17.47,"eps":-15.531682,"divideRate":0,"volume":10312,"delay":0,"ttmEps":-15.531682,"open":16.1,"prevYearClose":18.36,"prevWeekClose":17.0391,"prevMonthClose":15.21,"prevQuarterClose":15.21,"fiveDayClose":14.7,"twentyDayClose":17.1,"sixtyDayClose":15.18},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":570288312,"yearFounded":2017,"address":"3 Sugar Creek Center Boulevard,Suite 525,Sugar Land,Texas,United States","zipCode":"77478","officePhone":"832-413-1362"},"stockCompanyDetail":{"websiteUrl":"http://tvarditherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1675},{"period":"1month","weight":0.0923},{"period":"3month","weight":0.2214},{"period":"6month","weight":0.7854},{"period":"1year","weight":-0.3533},{"period":"ytd","weight":-0.0719}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.042039},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019771},{"month":3,"riseRate":0.583333,"avgChangeRate":0.021822},{"month":4,"riseRate":0.25,"avgChangeRate":-0.091823},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.001774},{"month":6,"riseRate":0.636364,"avgChangeRate":-0.002947},{"month":7,"riseRate":0.454545,"avgChangeRate":0.089214},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.002014},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.067808},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.031996},{"month":11,"riseRate":0.545455,"avgChangeRate":0.051738},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.02182}],"exchange":"NASDAQ","name":"Tvardi Therapeutics Inc","nameEN":"Tvardi Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":{"directors":[{"name":"Derek Chalmers","position":"Director,President and Chief Executive Officer"},{"name":"Dean Slagel","position":"Director"},{"name":"Harrison M. Bains, Jr.","position":"Director"},{"name":"Jeffrey L. Ives","position":"Director"},{"name":"Martin Vogelbaum","position":"Director"}],"executives":[{"name":"Derek Chalmers","position":"Director,President and Chief Executive Officer"},{"name":"Josef Schoell","position":"Treasurer, Chief Financial Officer"},{"name":"Frederique Menzaghi","position":"Vice President - Research and Development"},{"name":"Joseph Stauffer","position":"Chief Medical Officer"},{"name":"Michael E. Lewis","position":"Chief Scientific Advisor"},{"name":"Scott M. Terrillion","position":"General Counsel, Secretary"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-16","symbol":"TVRD","defaultRemindTime":1744810200000,"type":"split","dateTimestamp":1744776000000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-03-11","symbol":"TVRD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-12-31","symbol":"TVRD","defaultRemindTime":1735655400000,"type":"split","dateTimestamp":1735621200000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2024-11-14","symbol":"TVRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2024-08-14","symbol":"TVRD","fiscalQuarterEnding":"2024/06","expectedEps":-0.29,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{}}}